XML 34 R22.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2024

The Company is the lessee for operating leases for offices, R&D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities. For a discussion of lessor activities, see Note 13, "Revenue recognition."

The components of lease expense were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Operating lease cost:
Amortization of right-of-use assets	$	0.9	$	0.9	$	1.8	$	2.0
Interest on lease liabilities	0.2		0.2		0.4		0.4
Total operating lease cost	$	1.1	$	1.1	$	2.2	$	2.4

Operating lease costs are reflected as components of "Cost of Commercial Product sales", "Cost of MCM Product sales", "Cost of Bioservices", "R&D" expense and "SG&A" expense on the Company's Condensed Consolidated Statements of Operations.

Supplemental balance sheet information related to lessee activities is as follows:


Leases	Classification	June 30, 2024			December 31, 2023
Operating lease right-of-use assets	Other assets	$	13.7		$	16.2

Operating lease liabilities, current portion	Other current liabilities	$	3.1		$	3.5
Operating lease liabilities	Other liabilities	11.5			13.8
Total operating lease liabilities		$	14.6		$	17.3

Operating leases:
Weighted average remaining lease term (years)		6.1			6.2
Weighted average discount rate		5.3		%	5.3		%